EIT Pharma Raises $35M for Hepatitis D Drug
EIT Pharma closed a $35M Series A to advance infectious-disease therapies including a hepatitis D programme.
Not every strong life-sciences startup signal has to be AI-native. Late-stage regulatory progress can be just as important.
What happened
EIT Pharma closed an oversubscribed $35M Series A led by Propel Bio Partners.
The company is focused on infectious-disease therapies, including lonafarnib for chronic hepatitis D. The financing supports a programme that has already reached a later regulatory stage, including acceptance of a New Drug Application.
Why it matters
This is a more mature biotech financing than an early discovery platform round. Chronic hepatitis D is a serious infectious-disease market, and late-stage regulatory positioning makes the capital more directly linked to potential commercial and clinical milestones.
For investors, the signal is a continued willingness to fund focused biotech companies when there is a clear disease area, regulatory path and differentiated asset.
The bigger picture
The life-sciences funding market is still selective, but not closed. Capital is flowing toward companies that can show a credible bridge from science to approval, especially in areas where existing treatment options remain limited.